Back to top
more

C4 Therapeutics (CCCC)

(Delayed Data from NSDQ)

$2.12 USD

2.12
750,604

+0.07 (3.41%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

Zacks Equity Research

Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 223% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck

by Zacks Equity Research

C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.

Zacks Equity Research

Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 8.97% and 43.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, C4 Therapeutics, Inc. (CCCC) closed at $6.51, marking a -1.96% move from the previous day.

Zacks Equity Research

Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 227.3% upside potential for C4 Therapeutics, Inc. (CCCC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 8.70% and 5.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season

by Zacks Equity Research

C4 Therapeutics (CCCC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.